Essayer OR - Gratuit
PFC's Withdrawals Could Hit New Zero-Coupon Debt Sales
Mint Mumbai
|June 13, 2025
These bonds, often issued by govt entities, are primarily used for infrastructure financing
Issuer interest in zero-coupon bonds (ZCBs) faces a potential setback after state-run Power Finance Corporation (PFC) pulled its planned offering for a second time in a row, reportedly due to a mismatch in yield expectations, experts said.
Following approval from the Central Board of Direct Taxes (CBDT) on 11 March 2025, PFC decided to launch its 10-year zero-coupon bonds, according to an official notification, with a base issue size of ₹1,500 crore and a green shoe option to raise additional ₹1,500 crore in the event of high demand from investors.
Business Standard reported on Monday, citing sources, that PFC has withdrawn its zero-coupon bond issuance for the second time in just over a month, as investors demanded higher yields than what the issuer was willing to offer. PFC had previously withdrawn the issuance on 30 April 2025.
"The subdued response on Monday (to the PFC bond issuance) from both arrangers and investors suggests that issuers may need to revisit their strategy, timing, and pricing assumptions. Although CBDT approvals provide flexibility over the issuance window, market conditions will ultimately dictate whether ZCBs can sustain their relevance," said Venkatakrishnan Srinivasan, founder and managing partner of financial advisory firm Rockfort Fincap LLP.
Cette histoire est tirée de l'édition June 13, 2025 de Mint Mumbai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

